Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Sells $275,000.00 in Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWNGet Rating) CEO Jeremy Bender sold 12,500 shares of the stock in a transaction dated Monday, January 23rd. The shares were sold at an average price of $22.00, for a total transaction of $275,000.00. Following the completion of the sale, the chief executive officer now owns 1,181,486 shares of the company’s stock, valued at approximately $25,992,692. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Jeremy Bender also recently made the following trade(s):

  • On Wednesday, December 21st, Jeremy Bender sold 12,500 shares of Day One Biopharmaceuticals stock. The shares were sold at an average price of $20.32, for a total transaction of $254,000.00.
  • On Monday, November 21st, Jeremy Bender sold 12,500 shares of Day One Biopharmaceuticals stock. The shares were sold at an average price of $20.76, for a total transaction of $259,500.00.
  • On Wednesday, November 16th, Jeremy Bender sold 1,513 shares of Day One Biopharmaceuticals stock. The shares were sold at an average price of $21.46, for a total transaction of $32,468.98.
  • On Tuesday, November 1st, Jeremy Bender sold 12,500 shares of Day One Biopharmaceuticals stock. The shares were sold at an average price of $20.03, for a total transaction of $250,375.00.

Day One Biopharmaceuticals Price Performance

NASDAQ:DAWN traded up $0.25 on Tuesday, reaching $22.03. 341,972 shares of the company’s stock were exchanged, compared to its average volume of 780,825. Day One Biopharmaceuticals, Inc. has a 52 week low of $5.44 and a 52 week high of $28.35. The stock has a fifty day simple moving average of $21.28 and a 200-day simple moving average of $21.08.

Day One Biopharmaceuticals (NASDAQ:DAWNGet Rating) last issued its earnings results on Monday, November 7th. The company reported ($0.53) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.53). Equities analysts forecast that Day One Biopharmaceuticals, Inc. will post -2.18 EPS for the current year.

Hedge Funds Weigh In On Day One Biopharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. FMR LLC boosted its position in shares of Day One Biopharmaceuticals by 163.1% in the second quarter. FMR LLC now owns 6,826,574 shares of the company’s stock valued at $122,196,000 after acquiring an additional 4,232,055 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Day One Biopharmaceuticals by 5,969.9% in the second quarter. Goldman Sachs Group Inc. now owns 1,894,537 shares of the company’s stock valued at $33,912,000 after acquiring an additional 1,863,325 shares during the period. State Street Corp boosted its position in shares of Day One Biopharmaceuticals by 469.1% in the third quarter. State Street Corp now owns 2,041,738 shares of the company’s stock valued at $40,896,000 after acquiring an additional 1,682,955 shares during the period. Deerfield Management Company L.P. Series C boosted its position in shares of Day One Biopharmaceuticals by 68.3% in the second quarter. Deerfield Management Company L.P. Series C now owns 3,512,123 shares of the company’s stock valued at $62,867,000 after acquiring an additional 1,425,674 shares during the period. Finally, Franklin Resources Inc. boosted its position in shares of Day One Biopharmaceuticals by 59.8% in the second quarter. Franklin Resources Inc. now owns 2,465,380 shares of the company’s stock valued at $44,130,000 after acquiring an additional 922,521 shares during the period. Institutional investors own 86.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Bank of America assumed coverage on shares of Day One Biopharmaceuticals in a report on Thursday, December 1st. They set a “buy” rating and a $34.00 price objective for the company. Needham & Company LLC assumed coverage on shares of Day One Biopharmaceuticals in a report on Wednesday, December 14th. They set a “buy” rating and a $40.00 price objective for the company. The Goldman Sachs Group raised their price objective on shares of Day One Biopharmaceuticals from $45.00 to $62.00 and gave the stock a “buy” rating in a report on Monday, January 9th. HC Wainwright raised their price objective on shares of Day One Biopharmaceuticals from $35.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, January 9th. Finally, Piper Sandler raised their price objective on shares of Day One Biopharmaceuticals from $40.00 to $45.00 and gave the stock an “overweight” rating in a report on Sunday, January 8th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $43.50.

Day One Biopharmaceuticals Company Profile

(Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.

Further Reading

Insider Buying and Selling by Quarter for Day One Biopharmaceuticals (NASDAQ:DAWN)

Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.